Wir sind mit live! Mehr erfahren

Septerna Inc

SEPN

Börsenwert 1,7 Mrd. $

36,35 USD

-1,10

2,94 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

36,35

0,00

0 %

1 Tag

-2,94 %

5 Tage

-5,14 %

1 Monat

-5,44 %

3 Monate

15,18 %

6 Monate

45,46 %

Seit Jahresbeginn

29,91 %

1 Jahr

61,05 %

5 Jahre

69,86 %

10 Jahre

69,86 %

Profil: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Mitarbeiter: 130

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 20 %

Neutral 80 %

Negativ 0 %

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company's common stock to Rajiv Patni, M.D., the Company's newly appointed Chief Medical Officer, under the Company's 2026 Inducement Plan (the “Inducement Plan”). The inducement grant was effective as of September 8, 2026. The award was granted as an inducement material to Dr. Patni's employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:

Septerna to Participate in Upcoming Investor Conferences

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key catalyst.

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Zacks Investment Research

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

The Motley Fool

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

The Motley Fool

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, sel.

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Zacks Investment Research

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt